Related Experiment Video
Updated: May 16, 2026

Microbiological Rapid On-Site Evaluation for Pulmonary Infectious Diseases
Published on: March 1, 2024
Pulmonary cryptococcosis in non-AIDS patients
Jin-Quan Yu1, Ke-Jing Tang, Bing-Ling Xu
1Department of Pulmonary Medicine, The First Affiliated Hospital of Sun Yat-sen University, 58 ZhongShan Rd., Guangzhou, Guangdong, China.
Pulmonary cryptococcosis in non-acquired immunodeficiency syndrome (AIDS) patients is effectively managed with antifungal therapy and surgery. These patients demonstrate a good prognosis, with no reported relapse, dissemination, or death after appropriate treatment.
Area of Science:
- Pulmonology
- Infectious Diseases
- Mycology
Background:
- Pulmonary cryptococcosis is a fungal infection that can affect individuals without acquired immunodeficiency syndrome (AIDS).
- Understanding the clinical presentation and outcomes in non-AIDS patients is crucial for effective management.
Purpose of the Study:
- To investigate the clinical features, management strategies, and prognosis of pulmonary cryptococcosis in patients without AIDS.
- To evaluate the effectiveness of current treatment modalities in this specific patient population.
Main Methods:
- Retrospective study of 24 non-AIDS patients with pathologically confirmed pulmonary cryptococcosis.
- Analysis of clinical data, including symptoms, comorbidities, radiological findings (chest CT), diagnostic methods (biopsy), treatment approaches (surgery, antifungal therapy), and patient outcomes.
Main Results:
- The study included 24 patients (15 male, 9 female) aged 24-65 years, with 13 having comorbidities.
- Common symptoms included cough, chest tightness, expectoration, and fever. Chest CT revealed pulmonary nodules, masses, or consolidations, predominantly in lower lobes.
- Treatment involved surgery (9 patients) and/or antifungal therapy (fluconazole, voriconazole). No concurrent cryptococcal meningitis was observed.
Conclusions:
- Non-AIDS patients with pulmonary cryptococcosis exhibit a favorable prognosis when managed appropriately.
- Combined surgical resection and antifungal therapy appear effective, with no observed relapses or mortality in the follow-up period.
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pneumonia I: Introduction
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia I: Introduction
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...